Skip to main content
Erschienen in: Cancer Causes & Control 8/2008

01.10.2008 | Original Paper

Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California

verfasst von: Arti Parikh-Patel, Richard H. White, Mark Allen, Rosemary Cress

Erschienen in: Cancer Causes & Control | Ausgabe 8/2008

Einloggen, um Zugang zu erhalten

Abstract

Objective

We conducted a retrospective cohort study to examine cancer risk in a large cohort of systemic lupus erythematosus (SLE) patients in California.

Methods

The cohort consisted of individuals with SLE derived from statewide patient discharge data during the period 1991–2002. SLE patients were followed using cancer registry data to examine patterns of cancer development. Standardized incidence ratios (SIRs) and 95% CI were calculated to compare the observed to expected numbers of cancers based on age-, race-, and sex-specific incidence rates in the California population.

Results

The 30,478 SLE patients were observed for 157,969 person-years. A total of 1,273 cancers occurred within the observation interval. Overall cancer risk was significantly elevated (SIR = 1.14, 95% CI = 1.07–1.20). SLE patients had higher risks of vagina/vulva (SIR = 3.27, 95% CI = 2.41–4.31) and liver cancers (SIR = 2.70, 95% CI = 1.54–4.24). Elevated risks of lung, kidney, and thyroid cancers and several hematopoietic malignancies were also observed. Individuals had significantly lower risks of several screenable cancers, including breast, cervix, and prostate.

Conclusions

These data suggest that risks of several cancer types are elevated among SLE patients. Detailed studies of endogenous and exogenous factors that drive these associations are needed.
Literatur
1.
Zurück zum Zitat Abu-Shakra M, Buskila D, Shoenfeld Y (2000) SLE and cancer. In: Shoenfeld Y, Gershwin ME (eds) Cancer and autoimmunity. Elsevier Science, pp 31–40 Abu-Shakra M, Buskila D, Shoenfeld Y (2000) SLE and cancer. In: Shoenfeld Y, Gershwin ME (eds) Cancer and autoimmunity. Elsevier Science, pp 31–40
2.
Zurück zum Zitat Abu-Shakra M, Gladman DD, Urowitz MB (2004) Mortality studies in SLE: how far can we improve survival of patients with SLE. Autoimmun Rev 3:418–420PubMedCrossRef Abu-Shakra M, Gladman DD, Urowitz MB (2004) Mortality studies in SLE: how far can we improve survival of patients with SLE. Autoimmun Rev 3:418–420PubMedCrossRef
3.
Zurück zum Zitat Stahl-Hallengren C, Jonsen A, Nived O, Sturfelt G (2000) Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 27:685–691PubMed Stahl-Hallengren C, Jonsen A, Nived O, Sturfelt G (2000) Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 27:685–691PubMed
4.
Zurück zum Zitat Urowitz MB, Gladman DD (2000) How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology (Oxford) 39:238–244CrossRef Urowitz MB, Gladman DD (2000) How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology (Oxford) 39:238–244CrossRef
5.
Zurück zum Zitat Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT (1997) Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol 24:1061–1065PubMed Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT (1997) Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol 24:1061–1065PubMed
6.
Zurück zum Zitat Bernatsky S, Boivin JF, Joseph L et al (2005) An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 52:1481–1490PubMedCrossRef Bernatsky S, Boivin JF, Joseph L et al (2005) An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 52:1481–1490PubMedCrossRef
7.
Zurück zum Zitat Bernatsky S, Ramsey-Goldman R, Rajan R et al (2005) Non-Hodgkin’s lymphoma in systemic lupus erythematosus. Ann Rheum Dis 64:1507–1509PubMedCrossRef Bernatsky S, Ramsey-Goldman R, Rajan R et al (2005) Non-Hodgkin’s lymphoma in systemic lupus erythematosus. Ann Rheum Dis 64:1507–1509PubMedCrossRef
8.
Zurück zum Zitat Bjornadal L, Lofstrom B, Yin L, Lundberg IE, Ekbom A (2002) Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 31:66–71PubMedCrossRef Bjornadal L, Lofstrom B, Yin L, Lundberg IE, Ekbom A (2002) Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 31:66–71PubMedCrossRef
9.
Zurück zum Zitat Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH (1997) Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 40:761–768PubMedCrossRef Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH (1997) Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 40:761–768PubMedCrossRef
10.
Zurück zum Zitat Pettersson T, Pukkala E, Teppo L, Friman C (1992) Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 51:437–439PubMedCrossRef Pettersson T, Pukkala E, Teppo L, Friman C (1992) Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 51:437–439PubMedCrossRef
11.
Zurück zum Zitat Ragnarsson O, Grondal G, Steinsson K (2003) Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus 12:687–691PubMedCrossRef Ragnarsson O, Grondal G, Steinsson K (2003) Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus 12:687–691PubMedCrossRef
12.
Zurück zum Zitat Xu Y, Wiernik PH (2001) Systemic lupus erythematosus and B-cell hematologic neoplasm. Lupus 10:841–850PubMedCrossRef Xu Y, Wiernik PH (2001) Systemic lupus erythematosus and B-cell hematologic neoplasm. Lupus 10:841–850PubMedCrossRef
13.
Zurück zum Zitat Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165:2337–2344PubMedCrossRef Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165:2337–2344PubMedCrossRef
14.
Zurück zum Zitat Ramsey-Goldman R, Mattai SA, Schilling E et al (1998) Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med 46:217–222PubMed Ramsey-Goldman R, Mattai SA, Schilling E et al (1998) Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med 46:217–222PubMed
15.
Zurück zum Zitat Sweeney DM, Manzi S, Janosky J et al (1995) Risk of malignancy in women with systemic lupus erythematosus. J Rheumatol 22:1478–1482PubMed Sweeney DM, Manzi S, Janosky J et al (1995) Risk of malignancy in women with systemic lupus erythematosus. J Rheumatol 22:1478–1482PubMed
16.
17.
Zurück zum Zitat Bernatsky S, Clarke A, Ramsey-Goldman R (2002) Malignancy and systemic lupus erythematosus. Curr Rheumatol Rep 4:351–358PubMedCrossRef Bernatsky S, Clarke A, Ramsey-Goldman R (2002) Malignancy and systemic lupus erythematosus. Curr Rheumatol Rep 4:351–358PubMedCrossRef
18.
Zurück zum Zitat Oertel SH, Riess H (2002) Immunosurveillance, immunodeficiency and lymphoproliferations. Recent Results Cancer Res 159:1–8PubMed Oertel SH, Riess H (2002) Immunosurveillance, immunodeficiency and lymphoproliferations. Recent Results Cancer Res 159:1–8PubMed
19.
Zurück zum Zitat Bhalla R, Ajmani HS, Kim WW, Swedler WI, Lazarevic MB, Skosey JL (1993) Systemic lupus erythematosus and Hodgkin’s lymphoma. J Rheumatol 20:1316–1320PubMed Bhalla R, Ajmani HS, Kim WW, Swedler WI, Lazarevic MB, Skosey JL (1993) Systemic lupus erythematosus and Hodgkin’s lymphoma. J Rheumatol 20:1316–1320PubMed
20.
Zurück zum Zitat Black KA, Zilko PJ, Dawkins RL, Armstrong BK, Mastaglia GL (1982) Cancer in connective tissue disease. Arthritis Rheum 25:1130–1133PubMedCrossRef Black KA, Zilko PJ, Dawkins RL, Armstrong BK, Mastaglia GL (1982) Cancer in connective tissue disease. Arthritis Rheum 25:1130–1133PubMedCrossRef
21.
Zurück zum Zitat Canoso JJ, Cohen AS (1974) Malignancy in a series of 70 patients with systemic lupus erythematosus. Arthritis Rheum 17:383–390PubMedCrossRef Canoso JJ, Cohen AS (1974) Malignancy in a series of 70 patients with systemic lupus erythematosus. Arthritis Rheum 17:383–390PubMedCrossRef
22.
Zurück zum Zitat Green JA, Dawson AA, Walker W (1978) Systemic lupus erythematosus and lymphoma. Lancet 2:753–756PubMedCrossRef Green JA, Dawson AA, Walker W (1978) Systemic lupus erythematosus and lymphoma. Lancet 2:753–756PubMedCrossRef
23.
Zurück zum Zitat Abu-Shakra M, Gladman DD, Urowitz MB (1996) Malignancy in systemic lupus erythematosus. Arthritis Rheum 39:1050–1054PubMedCrossRef Abu-Shakra M, Gladman DD, Urowitz MB (1996) Malignancy in systemic lupus erythematosus. Arthritis Rheum 39:1050–1054PubMedCrossRef
24.
Zurück zum Zitat Cibere J, Sibley J, Haga M (2001) Systemic lupus erythematosus and the risk of malignancy. Lupus 10:394–400PubMedCrossRef Cibere J, Sibley J, Haga M (2001) Systemic lupus erythematosus and the risk of malignancy. Lupus 10:394–400PubMedCrossRef
25.
Zurück zum Zitat Nived O, Bengtsson A, Jonsen A, Sturfelt G, Olsson H (2001) Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus 10:500–504PubMedCrossRef Nived O, Bengtsson A, Jonsen A, Sturfelt G, Olsson H (2001) Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus 10:500–504PubMedCrossRef
26.
Zurück zum Zitat Sultan SM, Ioannou Y, Isenberg DA (2000) Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology (Oxford) 39:1147–1152CrossRef Sultan SM, Ioannou Y, Isenberg DA (2000) Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology (Oxford) 39:1147–1152CrossRef
27.
Zurück zum Zitat Services USDoHaH (2000) ICD-9-CM: international classification of diseases, 9th Revision, Clinical modification, 6th edition, Washington DC Services USDoHaH (2000) ICD-9-CM: international classification of diseases, 9th Revision, Clinical modification, 6th edition, Washington DC
28.
Zurück zum Zitat Cancer Reporting in California (1997) Standards for automated reporting. California cancer reporting system standards, vol II. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA, December 1997 Cancer Reporting in California (1997) Standards for automated reporting. California cancer reporting system standards, vol II. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA, December 1997
29.
Zurück zum Zitat Cancer Reporting in California (1997) Data standards for regional registries and California Cancer Registry. California cancer reporting system standards, vol III. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA, December 1997 Cancer Reporting in California (1997) Data standards for regional registries and California Cancer Registry. California cancer reporting system standards, vol III. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA, December 1997
30.
Zurück zum Zitat Cancer Reporting in California (1998) Reporting procedures for physicians. California cancer reporting system standards, vol IV. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA, January 1998 Cancer Reporting in California (1998) Reporting procedures for physicians. California cancer reporting system standards, vol IV. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA, January 1998
31.
Zurück zum Zitat Cancer Reporting in California (1997) Abstracting and coding procedures for hospitals. California cancer reporting system standards, vol I. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA, June 1997 Cancer Reporting in California (1997) Abstracting and coding procedures for hospitals. California cancer reporting system standards, vol I. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA, June 1997
32.
Zurück zum Zitat Chen VW, Howe HL, Wu XC (2000) Cancer in North America, 1993–1997. Volume I: incidence. North American Association of Central Cancer Registries, Springfield Chen VW, Howe HL, Wu XC (2000) Cancer in North America, 1993–1997. Volume I: incidence. North American Association of Central Cancer Registries, Springfield
33.
Zurück zum Zitat Seiffert JE, Price WT, Gordon B (1990) The California tumor registry: a state-of-the-art model for a regionalized, automated, population-based registry. Top Health Rec Manage 11:59–73PubMed Seiffert JE, Price WT, Gordon B (1990) The California tumor registry: a state-of-the-art model for a regionalized, automated, population-based registry. Top Health Rec Manage 11:59–73PubMed
34.
Zurück zum Zitat Integrity Program (1999) Data reengineering environment software. Vality Technology Inc., Boston Integrity Program (1999) Data reengineering environment software. Vality Technology Inc., Boston
35.
Zurück zum Zitat Allen M (2001) Validation of OSHPD and CCR insurance status. California Association of Central Cancer Registries Technical Conference, Riverside, CA Allen M (2001) Validation of OSHPD and CCR insurance status. California Association of Central Cancer Registries Technical Conference, Riverside, CA
36.
Zurück zum Zitat Fritz A, Percy C, Jack A et al (2000) International classification of diseases for oncology, 3rd edn. World Health Organization, Geneva Fritz A, Percy C, Jack A et al (2000) International classification of diseases for oncology, 3rd edn. World Health Organization, Geneva
37.
Zurück zum Zitat Breslow NE, Day NE (1987) Statistical methods in cancer research, Volume II: the design and analysis of cohort studies. International Agency for Research on Cancer, Lyon Breslow NE, Day NE (1987) Statistical methods in cancer research, Volume II: the design and analysis of cohort studies. International Agency for Research on Cancer, Lyon
38.
Zurück zum Zitat Bernatsky S, Boivin JF, Joseph L et al (2002) Prevalence of factors influencing cancer risk in women with lupus: social habits, reproductive issues, and obesity. J Rheumatol 29:2551–2554PubMed Bernatsky S, Boivin JF, Joseph L et al (2002) Prevalence of factors influencing cancer risk in women with lupus: social habits, reproductive issues, and obesity. J Rheumatol 29:2551–2554PubMed
39.
Zurück zum Zitat Bruce IN, Gladman DD, Urowitz MB (1998) Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study. Clin Exp Rheumatol 16:435–440PubMed Bruce IN, Gladman DD, Urowitz MB (1998) Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study. Clin Exp Rheumatol 16:435–440PubMed
40.
Zurück zum Zitat McAlindon T, Giannotta L, Taub N, D’Cruz D, Hughes G (1993) Environmental factors predicting nephritis in systemic lupus erythematosus. Ann Rheum Dis 52:720–724PubMedCrossRef McAlindon T, Giannotta L, Taub N, D’Cruz D, Hughes G (1993) Environmental factors predicting nephritis in systemic lupus erythematosus. Ann Rheum Dis 52:720–724PubMedCrossRef
41.
Zurück zum Zitat Petri M, Perez-Gutthann S, Spence D, Hochberg MC (1992) Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 93:513–519PubMedCrossRef Petri M, Perez-Gutthann S, Spence D, Hochberg MC (1992) Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 93:513–519PubMedCrossRef
42.
Zurück zum Zitat Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J Jr (1999) Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 26:2363–2368PubMed Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J Jr (1999) Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 26:2363–2368PubMed
43.
Zurück zum Zitat Ahmed MM, Berney SM, Wolf RE et al (2006) Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus. Am J Med Sci 331:252–256PubMedCrossRef Ahmed MM, Berney SM, Wolf RE et al (2006) Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus. Am J Med Sci 331:252–256PubMedCrossRef
44.
Zurück zum Zitat Berthier S, Mougin C, Vercherin P et al (1999) Does a particular risk associated with papillomavirus infections exist in women with lupus? Rev Med Interne 20:128–132PubMed Berthier S, Mougin C, Vercherin P et al (1999) Does a particular risk associated with papillomavirus infections exist in women with lupus? Rev Med Interne 20:128–132PubMed
45.
Zurück zum Zitat Tam LS, Chan AY, Chan PK, Chang AR, Li EK (2004) Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 50:3619–3625PubMedCrossRef Tam LS, Chan AY, Chan PK, Chang AR, Li EK (2004) Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 50:3619–3625PubMedCrossRef
46.
Zurück zum Zitat Thomas RH, Ridley CM, Black MM (1985) Lichen sclerosus et atrophicus associated with systemic lupus erythematosus. J Am Acad Dermatol 13:832–833PubMedCrossRef Thomas RH, Ridley CM, Black MM (1985) Lichen sclerosus et atrophicus associated with systemic lupus erythematosus. J Am Acad Dermatol 13:832–833PubMedCrossRef
47.
Zurück zum Zitat Gibbons RB, Westerman E (1988) Acute nonlymphocytic leukemia following short-term, intermittent, intravenous cyclophosphamide treatment of lupus nephritis. Arthritis Rheum 31:1552–1554PubMedCrossRef Gibbons RB, Westerman E (1988) Acute nonlymphocytic leukemia following short-term, intermittent, intravenous cyclophosphamide treatment of lupus nephritis. Arthritis Rheum 31:1552–1554PubMedCrossRef
48.
Zurück zum Zitat Lishner M, Hawker G, Amato D (1990) Chronic lymphocytic leukemia in a patient with systemic lupus erythematosus. Acta Haematol 84:38–39PubMed Lishner M, Hawker G, Amato D (1990) Chronic lymphocytic leukemia in a patient with systemic lupus erythematosus. Acta Haematol 84:38–39PubMed
49.
Zurück zum Zitat Rosenthal NS, Farhi DC (1996) Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy. Am J Clin Pathol 106:676–679PubMed Rosenthal NS, Farhi DC (1996) Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy. Am J Clin Pathol 106:676–679PubMed
50.
Zurück zum Zitat Vasquez S, Kavanaugh AF, Schneider NR, Wacholtz MC, Lipsky PE (1992) Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents. J Rheumatol 19:1625–1627PubMed Vasquez S, Kavanaugh AF, Schneider NR, Wacholtz MC, Lipsky PE (1992) Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents. J Rheumatol 19:1625–1627PubMed
51.
Zurück zum Zitat Elliott RW, Essenhigh DM, Morley AR (1982) Cyclophosphamide treatment of systemic lupus erythematosus: risk of bladder cancer exceeds benefit. Br Med J (Clin Res Ed) 284:1160–1161 Elliott RW, Essenhigh DM, Morley AR (1982) Cyclophosphamide treatment of systemic lupus erythematosus: risk of bladder cancer exceeds benefit. Br Med J (Clin Res Ed) 284:1160–1161
52.
Zurück zum Zitat Ortiz A, Gonzalez-Parra E, Alvarez-Costa G, Egido J (1992) Bladder cancer after cyclophosphamide therapy for lupus nephritis. Nephron 60:378–379PubMed Ortiz A, Gonzalez-Parra E, Alvarez-Costa G, Egido J (1992) Bladder cancer after cyclophosphamide therapy for lupus nephritis. Nephron 60:378–379PubMed
53.
Zurück zum Zitat Thrasher JB, Miller GJ, Wettlaufer JN (1990) Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis. J Urol 143:119–121PubMed Thrasher JB, Miller GJ, Wettlaufer JN (1990) Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis. J Urol 143:119–121PubMed
54.
Zurück zum Zitat Bernatsky S, Boivin JF, Joseph L et al (2005) Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum 53:781–784PubMedCrossRef Bernatsky S, Boivin JF, Joseph L et al (2005) Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum 53:781–784PubMedCrossRef
55.
Zurück zum Zitat Alarcon GS, Calvo-Alen J, McGwin G et al (2006) Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis 65(9):1168–1174PubMedCrossRef Alarcon GS, Calvo-Alen J, McGwin G et al (2006) Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis 65(9):1168–1174PubMedCrossRef
56.
Zurück zum Zitat Bernatsky SR, Cooper GS, Mill C, Ramsey-Goldman R, Clarke AE, Pineau CA (2006) Cancer screening in patients with systemic lupus erythematosus. J Rheumatol 33:45–49PubMed Bernatsky SR, Cooper GS, Mill C, Ramsey-Goldman R, Clarke AE, Pineau CA (2006) Cancer screening in patients with systemic lupus erythematosus. J Rheumatol 33:45–49PubMed
57.
Zurück zum Zitat Katz JN, Barrett J, Liang MH et al (1997) Sensitivity and positive predictive value of Medicare Part B physician claims for rheumatologic diagnoses and procedures. Arthritis Rheum 40:1594–1600PubMedCrossRef Katz JN, Barrett J, Liang MH et al (1997) Sensitivity and positive predictive value of Medicare Part B physician claims for rheumatologic diagnoses and procedures. Arthritis Rheum 40:1594–1600PubMedCrossRef
58.
Zurück zum Zitat Löfström B, Backlin C, Sundström C, Ekbom A, Lundberg IE (2007) A closer look at non-Hodgkin’s lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis 66(12):1627–1632PubMedCrossRef Löfström B, Backlin C, Sundström C, Ekbom A, Lundberg IE (2007) A closer look at non-Hodgkin’s lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis 66(12):1627–1632PubMedCrossRef
59.
Zurück zum Zitat Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRef Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRef
Metadaten
Titel
Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California
verfasst von
Arti Parikh-Patel
Richard H. White
Mark Allen
Rosemary Cress
Publikationsdatum
01.10.2008
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 8/2008
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-008-9151-8

Weitere Artikel der Ausgabe 8/2008

Cancer Causes & Control 8/2008 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.